New therapeutic patents for Alzheimer’s disease

Bibliography

• ROGERS SL, FARLOW MR, DOODY RS, MOHS R, FRIED- HOFF LT, THE DONEPEZIL STUDY GROUP: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology (1998) 50:136–145.
   PubMed Web of Science ®Google Scholar
• •Study showing donepezil improves cognition in about 1 in 5 patients (10 mg dose) in mild to moderate AD (MMSE 10–26).
   Google Scholar
• COREY-BLOOM J, ANAND R, VEACH J FOR THE ENA 713 B352 STUDY GROUP: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. (1998) 1:55–65.
   Google Scholar
• MORRIS JC, CYRUS PA, ORAZEM J et al.: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology (1998) 50:1222–1230.
   PubMed Web of Science ®Google Scholar
• Donepezil update. DTB (1998) 36:60–61.
   Google Scholar
• Neurobiology of Alzheimer's Disease. Dawbarn D, Allen SJ (Eds.), BIOS Scientific Publishers, Oxford, UK (1995).
   Google Scholar
• Pathobiology of Alzheimer's Disease. Goate A, Ashall F (Eds.), Academic Press, London, UK (1995).
   Google Scholar
• Molecular Mechanisms of Dementia. Wasco W, Tanzi RE (Eds.), Humana Press, Totawa, NJ, USA (1997).
   Google Scholar
• BURNS A, LEVY R: Clinical Diversity in Late Onset Alz-heimer's Disease. OUP, Oxford, UK (1992).
   Google Scholar
• HARDY J, ALLSOP D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. (1991) 12:383–388.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ: Alzheimer's disease: a central role for amy-loid. J. Neuropathol. Exp. Neurol. (1994) 53:438–447.
   PubMedGoogle Scholar
• LARNER AJ: The cortical neuritic dystrophy of Alz-heimer's disease: nature, significance, and possible pathogenesis. Dementia (1995) 6:218–224.
   PubMedGoogle Scholar
• TERRY RD: The pathogenesis of Alzheimer's disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. (1996) 55:1023–1025.
   PubMed Web of Science ®Google Scholar
• ANDERTON BH, CALLAHAN L, COLEMAN P et al.: Den-dritic changes in Alzheimer's disease and factors that may underlie these changes. Prog. Neurobiol. (1998) 55:595–609.
   PubMedGoogle Scholar
• MATTSON MP: Cellular actions of 6-amyloid precursorprotein and its soluble and fibrillogenic derivatives. Physiol. Rev. (1997) 77:1081–1132.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, CHENG B, DAVIS D, BRYANT K, LIEBER-BURG I, RYDEL RE: 13 amyloid peptides destabilize cal-cium homeostasis and render human cortical neurons vulnerable to excitotoxicity. j Neurosci. (1992) 12:376–389.
   PubMed Web of Science ®Google Scholar
• JOSEPH R, HAN E: Amyloid 6-protein fragment 25-35causes activation of cytoplasmic calcium in neurons. Biochem. Biophys. Res. Commun. (1992) 184:1441–1447.
   PubMedGoogle Scholar
• MATTSON MP, FURUKAWA K, BRUCE AJ, MARK RJ, BLANC E: Calcium homeostasis and free radical metabolism as convergence points in the pathophysiology of demen-tia. In: Molecular Mechanisms of Dementia. Wasco W, Tanzi RE (Eds.), Humana Press, Totawa, NJ, USA (1997):103–143.
   Google Scholar
• LARNER AJ: Intracellular mechanisms of amyloid 6-pe-ptide A625-35 induced neurite outgrowth inhibition in vitro. Alzheimer's Reports (1998) 1:55–60.
   Google Scholar
• BEHL C, DAVIS JB, LESLEY R, SCHUBERT D: Hydrogen peroxide mediates amyloid 13 protein toxicity. Cell (1994) 77:817–827.
   PubMed Web of Science ®Google Scholar
• RICHARDSON JS, ZHOU Y: Free radical scavengers block the actions of 6-amyloid on neurons in tissue culture. In: Alzheimer's disease: From Molecular Biology to Therapy. Becker R, Giacobini E (Eds.), Birkhauser, Boston, USA (1997):323–327.
   Google Scholar
• LYRAS L, CAIRNS NJ, JENNER A, JENNER P, HALLIWELL B:An assessment of oxidative damage to proteins, lipids, and DNA in brains from patients with Alzheimer's dis-ease. J. Neurochem. (1997) 68:2061–2069.
   PubMed Web of Science ®Google Scholar
• •Systematic study of oxidative damage in AD brain.
   Google Scholar
• FRASER SP, SUH Y-H, DJAMGOZ MBA: Ionic effects of the Alzheimer's disease 6-amyloid precursor protein and its metabolic fragments. Trends Neurosci. (1997) 20:67–
   PubMedGoogle Scholar
• LARNER AJ, ROSSOR MN: Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid 6-peptides. Exp. Opin. Ther. Patents (1997) 7:1115–1127.
   Web of Science ®Google Scholar
• KOH J-Y, YANG LL, COTMAN CW: 6-amyloid protein in-creases the vulnerability of cortical neurons to excito-toxic damage. Brain Res. (1990) 533:315–320.
   PubMedGoogle Scholar
• LIPTON SA, ROSENBERG PA: Excitatory amino acids as a final common pathway for neurologic disorders. New Engl. J. Med. (1994) 330:613–622.
   PubMed Web of Science ®Google Scholar
• STEWART R: Cardiovascular factors in Alzheimer's dis-ease. J. Neurol. Neurosurg. Psychiatry (1998) 65:143–147.
   PubMed Web of Science ®Google Scholar
• APPEL SH: A unifying hypothesis for the cause of amyo-trophic lateral sclerosis, Parkinsonism, and Alz-heimer's disease. Ann. Neurol. (1981) 10:499–505.
   PubMed Web of Science ®Google Scholar
• SEIGER A, NORDBERG A, VAN HOLST H et al.: Intracra-nial infusion of purified nerve growth factor to an Alz-heimer patient: the first attempt of a possible future treatment strategy. Behav. Brain Res. (1993) 57:255–261.
   Google Scholar
• TREANOR J, BECK K, HEFTI F: Neuronal growth factors and Alzheimer's disease. In: Neurobiology of Alzheimer's disease. Dawbarn D, Allen SJ (Eds.), BIOS Scientific Publish-ers, Oxford, UK (1995):249–268.
   Google Scholar
• LARNER AJ, SOFRONIEW MV: Mechanisms of cellular damage and recovery. In: Handbook of Neurological Re-habilitation. Greenwood RJ et al. (Eds.), Churchill Living-stone, Edinburgh, UK (1999). (In Press).
   Google Scholar
• CITRON M, OLTERSDORF T, HAASS C et al: Mutation of the 6-amyloid precursor protein in familial Alz-heimer's disease increases 6-protein production. Na-ture (1992) 360:672–674.
   PubMed Web of Science ®Google Scholar
• SEUBERT P, VIGO-PELFREY C, ESCH F et al: Isolation and quantification of soluble Alzheimer's 6-peptide from biological fluids. Nature (1992) 359:325–327.
   PubMed Web of Science ®Google Scholar
• GAMES D, ADAMS D, ALESSANDRINI R eta].: Alzheimer-type neuropathology in transgenic mice overexpress-ing V717F 6-amyloid precursor protein. Nature (1995) 373:523–527.
   Google Scholar
• JOHNSON-WOOD K, LEE M, MOTTER R et al.: Amyloid precursor protein processing and A642 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. ScL USA (1997) 94:1550–1555.
   PubMed Web of Science ®Google Scholar
• SIMONIAN NA, COYLE JT: Oxidative stress in neurode-generative disease. Ann. Rev. Pharmacol. Toxicol. (1996) 36:83–106.
   PubMed Web of Science ®Google Scholar
• MANTHORPE M, FAGNANI R, SKAPER SD, VARON S: Anautomated colorimetric microassay for neurono-trophic factors. Dev. Brain Res. (1986) 25:191–198.
   Google Scholar
• LANGSTON JW, BALLARD P, TETRUD JW, IRWIN I: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 219:979–980.
   PubMed Web of Science ®Google Scholar
• ELLMAN GL, COURTNEY KD, ANDRES V, FEATHERSTONE RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. (1961) 7:88–95.
   PubMed Web of Science ®Google Scholar
• KINDT MV, YOUNGSTER SK, SONSALLA PK, DUVOISIN RC, HEIKKILA RE: Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopa-minergic neurotoxicity of the MPTP analog, 2' Me-MPTP. Eur. J. Pharmacol (1988) 146:313–318.
   PubMed Web of Science ®Google Scholar
• TOWNS MT, LARNER AJ, KEYNES RJ, COOK GMW, MCKAY P, SOFRONIEW MV: Acetylcholinesterase activity in aged erythrocytes in Alzheimer's disease. Alzheimer's Res. (1996) 2:169–171.
   Google Scholar
• THE PARKINSON STUDY GROUP: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl. J. Med. (1993) 328:176–183.
   PubMed Web of Science ®Google Scholar
• RIEKKINEN PJ, KOIVISTO KJ, HELKALA E-L, REINIKAINEN KJ, KILKKU 0, HEINONEN E: Rationale to treat Alz-heimer's disease with selegiline - can we prevent the progression of the disease? In: Alzheimer's Disease: From Molecular Biology to Therapy. Becker R, Giacobini E (Eds.), Birkhauser, Boston, USA (1997):343–347.
   Google Scholar
• •Study suggesting that the MAO-B inhibitor selegiline can significantly slow progression of some features of AD.
   Google Scholar
• YOUNKIN SG: Evidence that A642 is the real culprit in Alzheimer's disease. Ann. Neurol (1995) 37:287–288.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: Hypothesis: amyloid 6-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. Neurobiol. Aging (1999). (In Press).
   Google Scholar
• LARNER AJ: Hypothesis: physiological and pathologi-cal interrelationships of amyloid 6-peptide and the amyloid precursor protein. Bioessays (1995) 17:819–824.
   PubMed Web of Science ®Google Scholar
• OLNEY J: NMDA receptor hypofunction, excitotoxicity and Alzheimer's disease. Neurobiol. Aging (1995) 16:459–461.
   Google Scholar
• MUFSON EJ, CONNER JM, KORDOWER JH: Nerve growthfactor in Alzheimer's disease: defective retrograde transport to nucleus basalis. NeuroReport (1995) 6:1063–1066.
   PubMed Web of Science ®Google Scholar
• BAJAJ NPS, IRVING NG, LEIGH PN, MILLER CCJ: Alz-heimer's disease, amyotrophic lateral sclerosis, and transgenic mice. J. Neurol. Neurosurg. Psychiatry (1998) 64:711–715.
   Google Scholar
• PRICE DL, SISODIA SS: Mutant genes in familial Alz-heimer's disease and transgenic models. Ann. Rev. Neu-rosci. (1998) 21:479–505.
   PubMed Web of Science ®Google Scholar
• Transgenic animal model for Alzheimer's disease. Exp. Opin. Ther. Patents (1998) 8:729–732.
   Google Scholar
• LARNER AJ: The pathogenesis of Alzheimer's disease: an alternative to the amyloid hypothesis. J. Neuropa-thol. Exp. Neurol. (1997) 56:214–215.
   PubMedGoogle Scholar